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Abstract
A high serum concentration of enterolactone, an enterolignan produced by colonic microbiota from precursors in cereals,
vegetables, and fruits, is associated with reduced risk of acute coronary events. Probiotics and prebiotics modify colonic
metabolism and may affect the serum enterolactone concentration. The effects of a probiotic mixture alone and with galacto-
oligosaccharides (GOS) on serum enterolactone concentration and fecal metabolism were investigated in 18 healthy men.
Participants received 3 interventions, each for 2 wk: 1) probiotics [Lactobacillus rhamnosus strains GG (LGG) and LC705,
Propionibacterium freudenreichii ssp. shermanii JS, and Bifidobacterium breve Bb99, for a total amount of 23 1010 CFU/d]; 2)
probiotics and GOS 3.8 g/d; 3) probiotics, GOS, and rye bread (minimum 120 g/d). Serum enterolactone and fecal dry weight,
enzyme activities, pH, SCFA, lactic acid bacteria, bifidobacteria, propionibacteria, and the strains LGG and LC705 were
determined. The serumenterolactone concentration (nmol/L) tended to be decreased frombaseline [mean (95%CI) 18.6 (10.8–
26.4)]byprobioticsalone [15.2 (7.8–22.7);P=0.095],wasnotsignificantlyaffectedbyprobioticswithGOS[21.5 (13.2–29.8)], and
was increased by probiotics with GOS and rye bread [24.6 (15.4–33.7); P , 0.05]. Probiotics alone did not affect fecal b-
glucosidase activity and bifidobacteria, but probiotics with GOS decreased b-glucosidase activity and increased bifidobacteria
comparedwithbaseline (P,0.05) andwithprobiotics alone (P,0.01). In conclusion, this probioticmixturewith orwithoutGOS
does not significantly affect serum enterolactone concentration. Because probiotics with GOS decreased fecal b-glucosidase
activity but not serumenterolactone, the reduced fecalb-glucosidase,within the range of activitiesmeasured, does not seem to
limit the formation of enterolactone. J. Nutr. 141: 870–876, 2011.
Introduction
Increased serum enterolactone concentrations have been asso-
ciated with reduced risk of acute coronary events and death from
coronary heart disease and from cardiovascular disease (1–3).
Enterolactone is produced by colonic bacteria from plant-
derived precursor lignans, such as matairecinol, secoisolaricir-
esinol, pinoresinol, and lariciresinol (4,5), and possesses various
biological activities (6). Though consumption of lignan-
containing foods such as whole-grain cereals, beans, other
vegetables, and some fruits and berries (6) and constipation
appear to be among the most important determinants of serum
enterolactone concentration, they account for only a small part
of the differences in serum enterolactone concentrations be-
tween individuals (7,8). This suggests, along with the effects of
oral antimicrobials in decreasing serum enterolactone concen-
tration (9), that intestinal microbiota is very important in
the metabolism of lignans. The bacteria species that produce
enterolactone are beginning to be clarified. Formation of
enterolactone from one of the most abundant dietary lignans,
secoisolariciresinol diglucoside, involves phylogenetically di-
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verse bacteria, most of which belong to the dominant human
intestinal microbiota (10).
The intestinal microbiota of humans predominantly consist
of the phyla Bacteroidetes and Firmicutes, the latter including
genera Dorea, Eubacterium, Ruminococcus, Clostridium, Lac-
tobacillus, and Streptococcus as well as the species Faecalibacte-
rium prausnitzii (11). Also, members ofActinobacteria, including
the genus Bifidobacterium, are abundant in the intestine. Several
species of lactobacilli and bifidobacteria fulfill the criteria of
probiotics (12), “live microorganisms which when administered
in adequate amounts confer a health benefit on the host” (13).
They may modify fecal enzyme activity (14–20). Galacto-
oligosaccharides (GOS)11 are nondigestible carbohydrates that
stimulate the growth of colonic bifidobacteria and, to a lesser
extent, lactobacilli (21) and are considered prebiotics. They have
a history of safe commercial use (21). Theoretically, a combi-
nation of probiotics and prebiotics may enhance survival
and function of probiotics in addition to resident beneficial
microbes (12).
Our primary aim in this study was to investigate the effects of
a probiotic mixture alone and together with GOS on serum
enterolactone concentration. The secondary aim was to investi-
gate their effects on fecal metabolic activity. We used a probiotic
combination of Lactobacillus rhamnosus GG (LGG), L. rham-
nosus LC705 (LC705), Propionibacterium freudenreichii ssp.
shermanii JS, and Bifidobacterium breve Bb99 (Bb99). This
combination alleviates symptoms in irritable bowel syndrome
(IBS) and duringHelicobacter pylori eradication therapy (22,23).
Also, when administered together with GOS, it reduces eczema
and increases resistance to respiratory infections in infants
(24,25). Rye bread was included in this study, because rye has the
highest concentration of total lignans among cereal species (26)
and rye foods are known to increase the serum enterolactone
concentration (27). We hypothesized that the changes in fecal
enzyme activity caused by probiotics and prebiotics could alter
the production of enterolactone from its precursors.
Methods
Participants
Eighteen healthy Finnish men aged 30–60 y (mean 45 y) volunteered to
participate in this study. Before entering the study, the participants were
interviewed for illness, medication, diet, and smoking. Exclusion criteria
included antibiotic treatment for 4 wk before the intervention, chronic
gastrointestinal diseases, and the use of chemotherapeutics. Two
participants used medication for high blood pressure, 1 for heart disease,
1 for asthma, and 5 of the participants smoked. All participants con-
sumed an omnivorous diet. The study protocol was approved by the
Ethics Committee of the Foundation for Nutrition Research, Helsinki,
Finland, conforms to the provisions of the Declaration of Helsinki in
1995, and was carefully explained to the participants, who then gave
their written informed consent.
Study design
The study lasted for 11 wk and consisted of a 3-wk run-in period, a 6-wk
intervention period, and a 2-wk follow-up. Intervention consisted of
three 2-wk periods: 1) probiotics: juice with probiotic bacteria (65 mL/d,
resulting in 23 1010 CFU daily); 2) probiotics+GOS: juice with probiotic
bacteria (65 mL/d) and GOS (3.8 g/d); and 3) probiotics+GOS+rye
bread: juice with probiotic bacteria (65 mL/d), GOS (3.8 g/d), and a
minimum of 120 g/d whole-grain rye bread in addition to participants’
normal diet, which also included rye bread. The 3-wk run-in period and
the 2-wk follow-up period did not include any special treatment. The 2-wk
intervention was considered long enough based on a previous study
showing that enterolactone concentrations in plasma reflect dietary change
within 2 wk (28). Because of the substantial variation in serum
enterolactone concentrations between individuals (7), we chose a study
design with sequential interventions, where each participant served as his
own control. Wash-out periods were not included because of the
“additive” sequential interventions. During the study, the participants
were not allowed to eat seeds, nuts, and products containing probiotic
bacteria. The participants were instructed not to change their ordinary diet
during the study other than according to the interventions.
The probiotic juice (Valio) contained 2 Lactobacillus rhamnosus
strains, LGG (ATCC 53103, 5.9 3 1010 CFU/L) and LC705 (DSM7061,
1.3 3 1011 CFU/L), 1 bifidobacterium strain, Bb99 (DSM 13692, 5.7 3
109 CFU/L), and 1 propionibacterium strain, Propionibacterium freuden-
reichii ssp. shermanii JS (DSM7067, 13 1011 CFU/L). After the probiotics
period, 10.3 g GOS syrup (Valio) was added to the probiotic juice. The
syrup contained 37% pure GOS, resulting in a daily amount of 3.8 g GOS/
participant. The extra rye bread (Reissumies, Fazer Bakeries) specially
delivered to the participants for this study contained 62% rye flour and
12%fiber. Themean daily amount of the extra rye bread consumed during
the probiotics+GOS+rye bread period was 143 g (range 78–210 g),
resulting in a mean daily total (extra + usual) amount of 211 g (range 78–
351 g).
Questionnaires
Participants estimated the severity of gastrointestinal symptoms (stom-
achache, abdominal distension, flatulence, heartburn, loose stools, hard
stools) during the previous 2 wk by using a visual analogue scale
(100 mm, 0–100) at the end of each intervention period and at the end of
follow-up. During the probiotics+GOS+rye bread period, the partici-
pants recorded each day the amount of rye bread they consumed. Use of
nonpermitted food products (seeds, nuts, and products containing
probiotic bacteria) and medication during the previous 2 wk was
evaluated by the participants at the end of each intervention period and
at the end of follow-up. In addition, such use during the study was
controlled by a frequency questionnaire conducted at the end of the
follow-up period. Finally, the participants were asked at the end of the
follow-up period if there were changes in their body weight, alcohol use,
intake of fat, and exercise habits during the study.
Serum sample analysis
Blood samples were collected 5 times during the experiment at the end of
each period. The sampling was performed in the morning and always on
the same day of the week. Serum was separated from the blood samples
not more than 2 h after sampling. The samples were centrifuged and
stored at 2208C until analysis. Enterolactone analyses were made by
time-resolved fluoroimmunoassay (29,30). At baseline, the blood sample
was taken after an overnight fast, and serum cholesterol and TG as well
as blood glucose were analyzed by a biochemical analyzer (Reflotron IV,
Boehringer Mannheim). LDL-cholesterol was calculated according to
the following formula: total cholesterol – HDL-cholesterol – (0.45 3
TG).
Fecal sample analysis
Fecal samples were collected 5 times during the experiment, at the end of
every period. The participants were asked to freeze the samples
immediately and to keep them frozen until taken in a cooler with ice
packs to the study center. In the laboratory, the fecal samples were stored
at 2708C until further analysis.
Fecal pH and dry weight. The pH of the fecal samples was measured
with the Mettler Toledo InLab 427 electrode. For dry matter determi-
nation, ;1 g of fecal sample was weighed and dried in the oven (1058C
17 h), cooled down in an exicator to room temperature, and reweighed.
Fecal dry weight was expressed as a percent of the wet weight.
Fecal enzyme activities. Fecal activities of b-glucosidase and
b-glucuronidase were analyzed by a method described by Goldin et al.
11 Abbreviations used: Bb99, Bifidobacterium breve Bb99; GOS, galacto-
oligosaccharides; IBS, irritable bowel syndrome; LC705, Lactobacillus rhamno-
sus LC705; LGG, Lactobacillus rhamnosus GG.
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(31). For the determination of fecal urease activity, the enzyme reaction
was conducted at 378C (pH 7.4) in a total volume of 1.0 mL containing a
final concentration of 0.02 mol/L potassium phosphate buffer, 10mmol/L
urea, and fecal extract (0.2 mL). The reaction was terminated by the
addition of 0.1 mol/L sulfuric acid (9.0 mL). After the addition of 1.0 mL
of 10 mol/L sodium hydroxide, the ammonia content was determined
with an automated analyzer (Mira S, Roche) using a Boehringer
Mannheim Ammonia kit. Enzyme activities were expressed per gram
protein and consequently the protein content was determined with a
protein test kit (Bio-Rad Protein Assay, Bio-Rad Laboratories).
SCFA. For the SCFA and enzyme analyses, fecal samples were diluted
1:10 with 0.1 mol/L phosphate buffer and homogenized with a Stom-
acher blender, filtered, sonicated 1min at 48C, and centrifuged at 4503 g
for 15 min at 48C. The supernatant fraction was used for analysis. The
samples were stored at 2708C. The concentrations of acetic acid,
propionic acid, butyric acid, valeric acid, isovaleric acid, capronic
acid, and isocapronic acid were determined with the capillary gas
chromatograph (HP-6890, Hewlett-Packard) by adapting the method
of Hoverstad et al. (32).
Microbiological analyses. Fecal samples were homogenized 1:10 in
Wilkins-Chalgren broth (Oxoid Ltd) in an anaerobic chamber and serial
dilutions were plated on MRS-agar (LAB M, International Diagnostics
Group) for total lactic acid bacteria, raffinose agar (33) for bifidobac-
teria, and yeast extract lactose agar (34) supplemented with 1% (wt:v) of
b-glycerolphosphate (Merck) for propionibacteria. MRS plates were
incubated at 378C for 3 d, raffinose agar plates at 378C for 2 d, and yeast
extract lactose agar plates at 308C for 7 d, all anaerobically. LGG and
LC705 strains were analyzed by plating the diluted samples on MRS-
vancomycin (50 mg/L) agar and anaerobically cultivating for 2–3 d at
378C. In LGG and LC705 analyses, 20 isolates of every sample were
purified further on MRS agar with vancomycin and tested for lactose
utilization by anaerobically incubating overnight at 378C on MRS agar
(pH 7.2) containing bromocresol purple 0.005% and 2% lactose,
resulting in a yellow (LC705) or white (LGG) color due to lactose
utilization.
Statistical analysis
Serum enterolactone was the primary outcome variable studied. Fecal
enzyme activities, fecal bacterial counts, fecal pH and dry weight, SCFA,
and gastrointestinal symptoms were the secondary variables. The
variables were measured during the study at the end of each study
period, the run-in period, the 3 intervention periods, and the follow-up
period. The run-in period was considered as baseline and it was taken as
the reference period in the post hoc analyses. Gastrointestinal symptoms
were not assessed before the interventions started and therefore post hoc
comparisons to baseline were replaced by comparisons to the follow-up
period. ANOVA for repeated measurements or Friedman test, when
appropriate, were conducted to analyze the within-subject changes in the
primary and secondary variables during the study periods. ANOVA for
repeated measurements with Greenhouse-Geisser adjustment was ap-
plied when the sphericity assumption was violated. In the case of a
significant global P-value, the post hoc comparisons were performed
using paired samples t test or Wilcoxon’s Signed Rank test, when
appropriate. In general, 5 post hoc comparisons were conducted: the 3
intervention periods were compared with baseline, and probiotics+GOS
was compared with probiotics, and probiotics+GOS+rye bread was
compared with probiotics+GOS. Only in the analysis of secondary
variables were the post hoc comparisons Bonferroni corrected. The
association between serum enterolactone and the secondary variables
was analyzed using the Spearman rank correlation. Secondary variables,
such as fecal enzyme activities, were divided into 2 groups (median as a
cutoff point) and the Mann-Whitney U test was used to compare the
serum enterolactone concentrations between the groups. P ,0.05 was
considered significant. Statistical analyses were performed with SPSS
(release 15.0) software. Values in the text are means 6 SD unless
otherwise noted.
Results
Participant characteristics and compliance. At baseline, the
serum concentration in fasting participants of total cholesterol
was 5.29 6 1.15 mmol/L, of HDL cholesterol, 1.15 6
0.32 mmol/L, of LDL cholesterol, 3.53 6 0.92 mmol/L, of TG,
1.396 0.77mmol/L, and of fasting glucose, 5.346 0.70mmol/L.
None of the participants used antibiotics during the study. Three
used forbidden probiotic products once and 1 ate nuts once
during the study. The rest of the participants did not consume
any of the excluded products. One participant lost 1.5 kg during
the study, and 1 participant reported that his intake of fat and
alcohol decreased during the study. All the participants com-
pleted the study.
Gastrointestinal symptoms. Of individual symptoms, only
flatulence and abdominal distension changed during the study
(P, 0.02). These symptom scores were higher during the period
of probiotics+GOS+rye bread [median (IQR)] [49.5 (17.3–73.3)
and 23.0 (13.0–49.9)] than during the follow-up period [23.0
(10.8–41.3) and 12.5 (9.0–27.0)] (P , 0.01). Consequently, the
total symptom score changed during the study (P = 0.027), being
significantly higher during the period of probiotics+GOS+rye
bread [mean (95% CI)] [153.6 (108.1–199.1)] than during the
follow-up [96.5 (65.8–127.2)] (P = 0.025). There were no
significant changes in other gastrointestinal symptoms.
Serum enterolactone. The serum enterolactone concentration
tended to be lower during the probiotics period than at baseline
[mean difference (95%CI)23.4 nmol/L (27.4–0.7)] (P = 0.095)
but did not differ from baseline during the probiotics+GOS
period [mean difference (95% CI) 2.9 nmol/L (24.1–9.9)] (P =
0.39) (Table 1). On the other hand, during the period of
probiotics+GOS+rye bread, the serum enterolactone concentra-
tion was higher than at baseline [mean difference (95% CI)
TABLE 1 Men’s serum enterolactone concentrations during a run-in period, sequential 2-wk
interventions with probiotics, probiotics+GOS, and probiotics+GOS+rye bread, and a
follow-up period
Serum enterolactone,1
nmol/L n Run-in Probiotics Probiotics+GOS
Probiotics+GOS +
rye bread Follow-up P 2
All participants 18 18.6 (10.8–26.4) 15.2 (7.8–22.7) 21.5 (13.2–29.8) 24.6 (15.4–33.7)a 23.2 (13.5–32.8) 0.045
Subgroups by run-in enterolactone
,20 nmol/L 9 5.0 (0.4–9.5) 3.2 (1.0–5.5) 10.5 (1.8–19.2) 9.6 (2.3–16.9) 6.8 (0.4–13.1) 0.19
$20 nmol/L 9 32.3 (25.9–38.6) 27.3 (17.9–36.6) 32.6 (21.9–43.2) 39.5 (31.0–48.1) 39.5 (30.9–48.2) 0.096
1 Values are means (95% CI). aDifferent from run-in, P , 0.05.
2 ANOVA for repeated measures. P-value refers to the global test.
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6.0 nmol/L (0.3–11.6)] (P = 0.042). There were no significant
differences in serum enterolactone concentration between inter-
vention periods in subgroups by run-in serum enterolactone
concentration below and above 20 nmol/L.
Fecal pH and dry weight. Fecal pH was not significantly
changed during the study (Table 2). Fecal dry weight (percent)
was significantly lower during the probiotics+GOS and probi-
otics+GOS+rye bread periods than at baseline (Table 2). Fecal
dry weight was also lower during the probiotics+GOS period
than during the probiotics period.
Fecal enzyme activities. Fecal activity of b-glucosidase was
lower during the probiotics+GOS period than at baseline [mean
difference (95% CI) 25.4 nmol×min21×mg protein21 (29.3 to
21.5)] (P = 0.045) and during the probiotics period [27.2
nmol×min21×mg protein21 (211.3 to 23.1)] (P = 0.008) (Table
2). b-Glucosidase activity during the probiotics and probiotics+
GOS+rye bread periods did not significantly differ from base-
line. Activities of urease and b-glucuronidase were not signif-
icantly affected during the study (Table 2).
Fecal bacterial counts. Fecal counts of both Lactobacillus
strains administered, LGG and LC705, as well as of total
propionibacteria were significantly higher during each interven-
tion period than at baseline (Table 3). Total bifidobacteria
counts were significantly higher during the probiotics+GOS
period than at baseline and during the probiotics period. There
was no significant difference in total lactic acid bacteria during
the probiotics, probiotics+GOS, or probiotics+GOS+rye bread
periods from baseline.
Fecal SCFA. Total fecal SCFA content as well as fecal acetic
acid, propionic acid, butyric acid, valeric acid, isobutyric acid,
isovaleric acid, and caproic acid contents were not significantly
different between the intervention periods (Supplemental Table 1).
Associations between serum enterolactone and fecal
markers. We counted correlations between baseline values of
serum enterolactone (nmol/L) and several fecal markers. Serum
enterolactone concentration was not correlated with fecal pH or
fecal dry weight. Serum enterolactone was positively correlated
with b-glucosidase activity (nmol×min21×mg protein21) (r =
0.57; P = 0.013) and tended to be positively correlated with
urease (r = 0.46; P = 0.055) and b-glucuronidase (r = 0.45; P =
0.064) activity (nmol×min21×mg protein21). b-Glucosidase
activity was categorized according to the median (20.2
nmol×min21×mg protein21). The median serum enterolactone
was 2.2 and 29.5 nmol/L (P = 0.024) when the b-glucosidase
activity was below or above the median, respectively (Fig. 1A).
Serum enterolactone tended to be positively correlated with 2
fecal bacterial counts (CFU/g dry weight): total bifidobacteria
(r = 0.44; P = 0.067) and total lactic acid bacteria (r = 0.42; P =
0.086). Total bifidobacteria count was categorized according to
the median (44.9 CFU/g dry weight). The median serum
enterolactone was 2.2 and 29.5 nmol/L (P , 0.01) when the
count of total bifidobacteria was below or above the median,
respectively (Fig. 1B). Correlations between serum enterolac-
tone and other fecal bacteria were not significant. Serum
enterolactone was positively correlated with 3 SCFA (mmol/g
dry weight): isobutyric (r = 0.56; P = 0.021), isovaleric (r = 0.56;
P = 0.020), and caproic acids (r = 0.57; P = 0.019).
Discussion
Our aim in this study was to investigate the effects of a probiotic
mixture alone and together with GOS on the serum enter-
olactone concentration and fecal metabolic activity. We hypoth-
esized that GOS would enhance the colonic metabolism of
probiotics and resident microbiota and thus lead to a larger
change in the serum enterolactone concentration than probiotics
alone. However, consumption of probiotics alone or with GOS
did not have a significant effect on the serum enterolactone
concentration. This is in line with the results of a previous in
vitro study where LGG as well as 3 other Lactobacillus strains,
L. casei Shirota, L. johnsonii La1, and L. bulgaricus, and
Bifidobacterium lactis Bb12 did not convert a plant lignan
7-hydroxymatairecinol to enterolactone or to other metabolites
(36). However, rye bread consumption increased the serum
enterolactone concentration, consistent with a previous study
(27), probably due mainly to rye bread’s high lignan content
(26).
Lignans occur in plants as glucosides (10,37). In the present
study, the activity of fecal b-glucosidase was positively corre-
lated with the serum enterolactone concentration at baseline,
consistent with a previous in vitro study where there was a trend
toward positive correlation between b-glucosidase activity and
enterolactone production by human fecal bacteria (38). Activity
of fecal b-glucosidase was not significantly affected during the
period of probiotics alone but decreased during the probiotics
together with GOS treatment period compared both to baseline
TABLE 2 Men’s fecal pH, dry weight and enzyme activities during a run-in period, sequential 2-wk
interventions with probiotics, probiotics+GOS, and probiotics+GOS+rye bread, and a follow-
up period
Variable1 Run-in Probiotics Probiotics+GOS
Probiotics+GOS +
rye bread Follow-up P 2
Fecal pH 6.90 6 0.40 6.83 6 0.23 6.67 6 0.35 6.65 6 0.40 6.85 6 0.40 0.12
Fecal dry weight, % 19.6 6 0.77 19.4 6 1.12 18.4a,b 6 1.31 18.4c 6 1.20 18.9 6 1.36 0.007
Urease, nmolmin21mg protein21 32.5 6 26.6 32.6 6 23.1 23.0 6 12.5 30.9 6 21.9 35.9 6 18.3 0.20
b-glucuronidase, nmolmin21mg protein21 8.94 6 3.12 8.47 6 4.08 8.33 6 5.03 6.80 6 3.23 9.53 6 4.90 0.26
b-glucosidase, nmolmin21mg protein21 22.0 6 8.58 23.9 6 10.1 16.6a,d 6 5.32 18.2 6 4.72 23.3 6 7.86 0.001
1 Values are means 6 SD, n = 18 except pH, n = 16. aDifferent from run-in, P , 0.05; bdifferent from probiotics, P , 0.05; cdifferent from
run-in, P , 0.01; ddifferent from probiotics, P , 0.01.
2 Friedman’s 1-way ANOVA for fecal dry weight and ANOVA for repeated measures for other variables. P-value refers to the global test.
Bonferroni corrected comparisons.
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and to the period of probiotics alone, suggesting that GOS either
directly inhibited b-glucosidase activity or reduced the number
or metabolism of bacterial species with high b-glucosidase
activity. GOS addition led to very large and rapid reductions in
the activity of this enzyme in a previous study using an in vitro
human gut bacterial ecosystem, suggesting a direct inhibition
(39), and GOS reduced fecal b-glucosidase activity in healthy
men (40). However, in the present study, the decreased activity
of fecal b-glucosidase during the consumption of probiotics
together with GOS did not lead to decreased serum enter-
olactone concentrations, suggesting that despite a significant
correlation with serum enterolactone, within the range of ac-
tivities measured in the present study, fecal b-glucosidase does
not have a central role in modifying serum enterolactone
concentration.
Fecal counts of total propionibacteria, LC705, LGG, and total
bifidobacteria were increased by the interventions, whereas
counts of total lactic acid bacteria were not. The result that total
bifidobacteria counts were increased during probiotics with GOS,
compared with both baseline and probiotics alone, is in line with
a previous finding that GOS alone increased the bifidobacterial
population in healthy adults (41). In addition, trials using the
same probiotic mixture as the present study indicated that fecal
bifidobacteria counts significantly increased only when adminis-
tered with GOS in infants (24,42) and slightly decreased when
administered without GOS in IBS in adults (43). Total lactic acid
bacteria counts in these studies, on the other hand, increased in
infants given with or without GOS (24,42), although lactobacilli
counts have not changed in adults with IBS (43).
Certain bifidobacteria species have been shown to synthesize
high levels of b-glucosidase (44) and the administration of B.
breve increases fecal b-glucosidase activity in healthy adults
(45). In the present study, the increase in total bifidobacteria
counts during probiotics with GOS did not increase b-glucosidase
activity or serum enterolactone concentration. This suggests that
the positive correlation between fecal bifidobacteria counts and
serum enterolactone at baseline is explained by some other
variable than fecal b-glucosidase activity, such as the amount of
rye bread consumed, which has the potential to increase both
(27,46,47). It is also possible that those bifidobacteria strains that
increased during probiotics with GOS (Bb99 in the probiotic
mixture or resident strains) do not synthesize high levels of
b-glucosidase or that b-glucosidase activity is reduced by a direct
inhibition by GOS (39).
Fecal pH or SCFA concentrations did not significantly change
during the study. These findings are supported by previous
intervention studies. The same probiotic mixture (without GOS)
as that used in the present study had no significant effect on fecal
SCFA concentrations in adults with IBS (43). GOS reduced pH
and increased lactic acid and acetic acid concentrations in the
proximal, but not distal, colon of pigs, without a significant
effect on propionic acid and butyric acid concentrations in ei-
TABLE 3 Men’s fecal bacterial counts during a run-in period, sequential 2-wk interventions with
probiotics, probiotics+GOS, and probiotics+GOS+rye bread, and a follow-up period1
Fecal bacteria2 Run-in Probiotics Probiotics+GOS
Probiotics+GOS +
rye bread Follow-up P 3
log10 CFU/g dry weight
Total lactic acid bacteria 31.4 (27.1–35.2) 31.8 (28.5–33.8) 32.3 (30.1–38.3) 30.6 (24.4–32.9) 25.0 (16.1–30.7) 0.001
Total bifidobacteria 44.9 (40.7–46.6) 46.6 (43.5–51.1) 51.0a,b (48.6–55.1) 50.9 (44.5–54.3) 47.1 (34.7–51.4) 0.001
Total propionibacteria 10.4 (10.1–12.1) 30.5c (25.9–35.4) 32.6c (27.9–35.9) 33.6c (27.2–37.0) 10.7 (10.2–11.5) ,0.001
LC705 10.2 (9.9–10.6) 26.7c (23.6–30.3) 30.4c (24.8–34.0) 29.4c (23.9–30.2) 11.1 (10.4–20.8) ,0.001
LGG 10.2 (9.9–10.5) 24.5c (20.1–29.1) 29.4c (26.5–33.8) 24.1c (16.9–28.6) 10.7 (10.2–21.7) ,0.001
1 Values are medians (IQR), n = 18 during each period. aDifferent from run-in, P , 0.05; bdifferent from probiotics, P , 0.01; cdifferent from
run-in, P , 0.01.
2 Fecal counts of total lactic acid bacteria, total bifidobacteria, and total propionibacteria (expressed as log10 CFU/g wet weight) during run-
in, Probiotics and Probiotics+GOS treatments have been published (35).
3 Friedman’s 1-way ANOVA. P-value refers to the global test.
FIGURE 1 Serum enterolactone concentrations at baseline in men
with fecal b-glucosidase activity less than or greater than the median of
20.2 nmol×min21×mg protein21 (A) and with fecal bifidobacteria counts
less than or greater than the median of 44.9 log10 CFU/g dry weight (B).
Horizontal lines are medians (n = 9). *P , 0.03.
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ther (48). In healthy men, fecal pH and SCFA concentrations
remained unaltered during GOS administration, except for the
acetic acid concentration, which increased (40). In the present
study, rye bread together with probiotics and GOS appeared to
increase concentrations of several SCFA compared with probi-
otics alone or with GOS. In our previous study, rye bread
increased acetic acid, propionic acid, and butyric acid concen-
trations in feces and reduced fecal pH in constipated adults (49).
SCFA are challenging to measure from feces, because they are
efficiently absorbed from the colon, with only 10–20% being
excreted in the feces (50).
A previous study showed that enterolactone concentrations
in plasma reflected dietary change within 2 wk of the introduc-
tion of a new diet but they continued to increase for 4–6 wk (28).
On the basis of this previous study, perhaps the intervention of
2 wk was too short to detect the maximal effect of interventions
on serum enterolactone concentration. This is suggested by the
fact that serum enterolactone concentrations were high during
the follow-up.
In conclusion, the consumption of probiotics alone or with
GOS in the present study did not have a significant effect on the
serum enterolactone concentration, although probiotics with
GOS, but not alone, decreased fecal b-glucosidase activity. This
indicates that fecal b-glucosidase, at the activities measured,
does not have a major role in modifying the serum enterolactone
concentration.
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